Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 2,245 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fasting Clear all
Completed Not applicable Interventional

Effects of Different Types of Augmented Feedback on Intrinsic Motivation and Spatiotemporal Gait Performance After Stroke

NCT04740060
View directory record Official record
Conditions
Stroke, Hemiparesis, Walking, Difficulty
Interventions
Augmented Feedback without Virtual Reality(VR, Augmented Feedback with Non-Game based VR, Augmented Feedback with Game based VR
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

NCT02536391
View directory record Official record
Conditions
Cancer
Interventions
Ipatasertib (capsule), Ipatasertib (tablet)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 20, 2026, 5:25 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance Biomarkers in Nonalcoholic Fatty Liver Disease

NCT01930123
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
intravenous fructose challenge, Blood Draw
Drug · Other
Lead sponsor
Manal F Abdelmalek
Other
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Results available

Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas

NCT01898078
View directory record Official record
Conditions
Advanced Solid Tumors, Lymphoma
Interventions
Alisertib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
The Bronx, New York • Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing the Effect of Multiple Weight Management Modalities for Chronic Disease Risk Reduction in a Clinical Setting

NCT03998878
View directory record Official record
Conditions
Obesity
Interventions
Low-Carbohydrate Diet, Intermittent Energy Restriction, Hunger Training
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential

NCT02706535
View directory record Official record
Conditions
Drug Interactions, Neoplasms
Interventions
GSK525762 Besylate Tablets, Itraconazole 200 mg, Rifampicin 300 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Results available

The Efficacy of Doxazosin for Cocaine Users

NCT00880997
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Doxazosin, Placebo
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Acute Effects of Caloric Restriction on Anthropometrics, Metabolism, and Cardiovascular Health in Overweight Adults

NCT05422391
View directory record Official record
Conditions
Obesity, Overweight, Intermittent Fasting
Interventions
3 day caloric restriction/metabolic reset
Dietary Supplement
Lead sponsor
Skidmore College
Other
Eligibility
25 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Saratoga Springs, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Endothelial Function in Obese Adolescents

NCT01879033
View directory record Official record
Conditions
Insulin Resistance, Glucose Intolerance, Obesity, Atherosclerosis
Interventions
Reactive hyperemia peripheral artery tonometry (Rh-PAT), Blood levels for glucose, insulin, lipids and adipocytokines
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
12 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

NCT01846455
View directory record Official record
Conditions
Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma
Interventions
2.0mg Buprenorphine/0.5mg Naloxone, Promethazine
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Hialeah, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 20, 2026, 5:25 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Fasting on Newly Diagnosed Breast Cancer

NCT02379585
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Doxorubicin, cyclophosphamide, paclitaxel, docetaxel, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Between Colchicine and Ritonavir

NCT00983515
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Colchicine, Ritonavir
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting

NCT00835549
View directory record Official record
Conditions
Healthy
Interventions
Cefdinir for oral suspension 250 mg/5mL, OMNICEF® for oral suspension 250 mg/5mL
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions

NCT00934921
View directory record Official record
Conditions
Healthy
Interventions
Ondansetron, Zofran®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon

NCT00498615
View directory record Official record
Conditions
Raynaud, Scleroderma
Interventions
Fasudil
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations

NCT03112148
View directory record Official record
Conditions
Healthy
Interventions
10 mg dose MR formulations,10 mg dose of tofacitinib IR solution
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions

NCT01331447
View directory record Official record
Conditions
Breast Cancer
Interventions
exemestane
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Fasting Conditions

NCT00864526
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose, COMBONOX® tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effect of Food on LY3537982 in Healthy Participants

NCT05824858
View directory record Official record
Conditions
Healthy
Interventions
LY3537982
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of the Reversibility of Glucose Intolerance Caused by Chronic Aspartame Consumption

NCT02520258
View directory record Official record
Conditions
Glucose Metabolism Disorder
Interventions
Oral glucose tolerance test (OGTT), Diet soda containing aspartame only
Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity

NCT00897676
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin-(9-39), placebo
Drug
Lead sponsor
Diva De Leon
Other
Eligibility
6 Months to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 20, 2026, 5:25 AM EDT
Completed No phase listed Observational

Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?

NCT01865825
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Esophageal Barium Xray
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 20, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

NCT01663389
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 1000 mg containing radioactive 14C-GSK1322322, GSK1322322 1200 mg containing radioactive 14C-GSK1322322
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 20, 2026, 5:25 AM EDT
Not listed Phase 2 Interventional

Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

NCT01283789
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Lapatinib and RAD-001
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 20, 2026, 5:25 AM EDT